References
- Nowakowski GS, Chiappella A, Witzig TE, et al. ROBUST: lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Future Oncol. 2016;12(13):1553–1563.
- Younes A, Zinzani PL, Sehn LH, et al. A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2014;32(15_suppl):TPS8615.
- Davies AJ, Barrans S, Maishman T, et al. Differential efficacy of bortezomib in subtypes of diffuse large B-cell lymphoma (DLBCL): a prospective randomised study stratified by transcriptome profiling: REMODL-B. Hematol Oncol. 2017;35(Suppl S2):130–131.
- Morschhauser F, Feugier P, Flinn IW, et al. Venetoclax plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) improves outcomes in BCL2-positive first-line diffuse large B-cell lymphoma (DLBCL): first safety, efficacy and biomarker analyses from the phase II CAVALLI study. Blood. 2018;132(Supplement 1):782.
- Younes A, Sehn LH, Johnson P, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-Cell lymphoma. J Clin Oncol. 2019;37(15):1285–1295.
- Bartlett NL, Wilson WH, Jung SH, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-Cell lymphoma: clinical outcomes of the Phase III intergroup trial Alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790–1799.
- Maurer MJ, Ghesquières H, Link BK, et al. Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials. J Clin Oncol. 2018;36(16):1603–1610.
- Maurer MJ, Ghesquières H, Link BK, et al. Diagnosis-to-treatment interval (DTI) remains associated with adverse clinical characteristics and outcome in newly diagnosed patients with diffuse large B-cell lymphoma treated on clinical trials. Blood. 2017;130(Suppl 1):4115.
- Maurer MJ, Link BK, Habermann TM, et al. Time from diagnosis to initiation of treatment of DLBCL and implication for potential selection bias in clinical trials. Blood. 2016;128(22):3034.
- Vitolo U, Trněný M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35(31):3529–3537.
- Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301.
- Camus V, Dubois S, Jardin F, et al. Prognostic impact of diagnosis to treatment interval (DTI) in diffuse large B-cell lymphoma patients: a real-life monocentric study. Leuk Lymphoma. 2019;60(3):839–841.